Skip to main content
Premium Trial:

Request an Annual Quote

Axaron Inks Deal for Axaminer Technology with Max Planck Institute

NEW YORK, Jan. 26 (GenomeWeb News) - Axaron Bioscience said today that it has signed a service contract to provide its Axaminer gene expression profiling technology to the Max Planck Institute for Medical Research.


Under the arrangement, said Axaron, the technology will be used by Max Planck Institute researchers in a project analyzing the molecular processes of glutamate-mediated signal transduction.


"We are hoping these investigations will lead to a better understanding of neurological diseases such as stroke," Peter Seeburg, director of the department of molecular neurobiology at the Max Planck Institute, said in a statement.


Specific terms of the deal were not disclosed.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.